Browsing Tag
AbbVie
63 posts
Glenmark Pharmaceuticals surges 10% after AbbVie licensing deal boosts ISB 2001 global reach
Glenmark Pharmaceuticals stock jumps 10% after announcing ISB 2001 licensing deal with AbbVie; find out what this could mean for its oncology ambitions.
Why amylin is gaining pharma attention in obesity drug development: From amycretin to AZD6234
Discover how Novo Nordisk, AstraZeneca, and others are betting on amylin-based obesity drugs like amycretin and AZD6234 to reshape metabolic care.
AbbVie to acquire Capstan Therapeutics for $2.1bn to expand in vivo CAR-T platform for autoimmune therapy
AbbVie will acquire Capstan Therapeutics for $2.1B, gaining in vivo CAR-T platform and lead asset CPTX2309 in autoimmune therapy. Read full acquisition details.
REGENXBIO monetizes gene therapy royalties in $250m deal with HCRx
REGENXBIO advances strategic funding deal with Healthcare Royalty to monetize Zolgensma and pipeline royalties while preserving upside from NAV platform assets and AbbVie/Nippon Shinyaku partnerships.
AbbVie’s ELAHERE demonstrates 32% reduction in death risk for ovarian cancer patients
A final analysis of the Phase 3 MIRASOL trial has confirmed that ELAHERE (mirvetuximab soravtansine-gynx) provides a significant…
AbbVie to develop amylin analog for obesity treatment in $350m licensing deal with Gubra
AbbVie has taken a significant step into obesity treatment through a licensing agreement with Denmark-based Gubra, a company…
Xilio Therapeutics accelerates cancer immunotherapy with new masked T cell engager programs and $52m AbbVie collaboration
Xilio Therapeutics, Inc., a clinical-stage biotechnology company based in Waltham, Massachusetts, has announced the development of three new…
FDA approves EMBLAVEO to combat complicated intra-abdominal infections with limited treatment options
The U.S. Food and Drug Administration (FDA) has granted approval for EMBLAVEO (aztreonam and avibactam), marking a significant…
AbbVie reports 2024 financial results: Revenue growth driven by immunology and neuroscience
AbbVie (NYSE: ABBV) has released its full-year and fourth-quarter 2024 financial results, showing continued revenue growth despite challenges…
AbbVie to expand immunology pipeline with Nimble Therapeutics acquisition
In a significant move to solidify its presence in immunology, AbbVie has announced the acquisition of Nimble Therapeutics,…